当前位置: 首页 > 期刊 > 《新医学》 > 201911
编号:13527741
免疫检查点抑制剂的消化系统不良反应及其治疗(5)
http://www.100md.com 2019年11月1日 《新医学》 201911
     [22] Friedman CF, Clark V, Raikhel AV, Barz T, Shoushtari AN, Momtaz P, Callahan MK, Wolchok JD, Chapman PB, Hellmann MD, Postow MA. Thinking critically about classifying adverse events: incidence of pancreas in patients treated with nivolumab + ipilimumab. J Natl Cancer Inst, 2016, 109(4).doi: 10.1093/jnci/djw260.

    [23] Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book,2015,76-83.

    [24] Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, G?ppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Cutan-eous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer, 2016, 60: 190-209.

    [25] Abu-Sbeih H, Tang T, Lu Y, Thirumurthi S, Altan M, Jazaeri AA, Dadu R, Coronel E, Wang Y. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunother Cancer,2019,7(1):31.

    (收稿日期:2019-05-18)

    (本文編辑:杨江瑜), http://www.100md.com(刘光德?吕志诚)
上一页1 2 3 4 5